Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-09-30 | Direct | 39,634 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 39,634 · Balance 39,634 F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:16 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 39,634 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001878313-26-000097 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,634 Underlying: Common Stock · 39,634 shares Expires 2036-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:13 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 32,630 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001878313-26-000072 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,630 Underlying: Common Stock · 32,630 shares Expires 2036-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:53 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 33,748 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001878313-26-000035 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,748 Underlying: Common Stock · 33,748 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 13:39 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantOptions · Derivative | 29,789 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001878313-26-000012 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,789 Underlying: Common Stock · 29,789 shares Expires 2035-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 13:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseStock Options · Derivative | 81,699 | $1.36 Strike: $1.36 | $111,110.64 |
DisclosureSEC source: 0001878313-25-000069 · form4.xml · derivative · entry 2 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,699 Underlying: Common Stock · 81,699 shares Expires 2028-12-22 F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 13:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 81,699 | $1.22 | $99,999.58 |
DisclosureSEC source: 0001878313-25-000069 · form4.xml · nonDerivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248,888 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025 Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:24 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 25,331 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001878313-25-000031 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,331 Underlying: Common Stock · 25,331 shares Expires 2035-10-02 F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:16 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 25,232 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001127602-25-018655 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,232 Underlying: Common Stock · 25,232 shares Expires 2035-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:44 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 26,304 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001127602-25-011813 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,304 Underlying: Common Stock · 26,304 shares Expires 2035-04-04 F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:11 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 15,338 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001127602-25-000396 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,338 Underlying: Common Stock · 15,338 shares Expires 2034-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:47 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 10,848 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001127602-24-024938 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,848 Underlying: Common Stock · 10,848 shares Expires 2034-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of thate date. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:10 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 8,592 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001127602-24-019841 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,592 Underlying: Common Stock · 8,592 shares Expires 2034-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 21:33 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 19,665 | $2.26 Strike: $2.26 | $44,442.90 |
DisclosureSEC source: 0001127602-24-013490 · form4.xml · derivative · entry 2 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,665 Underlying: Common Stock · 19,665 shares Expires 2029-10-25 F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were deemed options issued under the Issuer's 2021 Equity Inventive Plan on April 25, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date. Read SEC document |
| April 25, 2024 Filed Apr 26, 2024 21:33 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 19,665 | $2.03 | $39,919.95 |
DisclosureSEC source: 0001127602-24-013490 · form4.xml · nonDerivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,167,189 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on April 25, 2024. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 20:59 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 13,790 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-24-011895 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,790 Underlying: Common Stock · 13,790 shares Expires 2034-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 23:09 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 170,940 | $1.30 Strike: $1.30 | $222,222.00 |
DisclosureSEC source: 0001127602-24-010325 · form4.xml · derivative · entry 2 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,940 Underlying: Common Stock · 170,940 shares Expires 2029-09-14 F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 23:09 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 170,940 | $1.17 | $199,999.80 |
DisclosureSEC source: 0001127602-24-010325 · form4.xml · nonDerivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,147,524 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 02:03 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 23,127 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001127602-24-000650 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,127 Underlying: Common Stock · 23,127 shares Expires 2033-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 20:11 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 12,567 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-23-025154 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,567 Underlying: Common Stock · 12,567 shares Expires 2033-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 12:16 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 13,365 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-23-019772 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,365 Underlying: Common Stock · 13,365 shares Expires 2033-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 10:49 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 48,000 | $2.25 | $108,000.00 |
DisclosureSEC source: 0001127602-23-013710 · form4.xml · nonDerivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976,584 F1 · kind: These shares were purchased by the reporting person in the issuer's follow-on offering, which closed on April 27, 2023. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 10:32 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 8,513 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001127602-23-012015 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,513 Underlying: Common Stock · 8,513 shares Expires 2033-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 23:18 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 4,568 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001127602-23-000683 · form4.xml · derivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,568 Underlying: Common Stock · 4,568 shares Expires 2032-12-30 F1 · derivative.exercise_date: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:40 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 20,000 | $5.00 | $100,000.00 |
DisclosureSEC source: 0000899243-22-027461 · doc4.xml · nonDerivative · entry 1 Louie Ngar Yee · CIK 0001913264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,584 F1 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.